1236 related articles for article (PubMed ID: 15194174)
1. Cellular and molecular pathobiology of pulmonary arterial hypertension.
Humbert M; Morrell NW; Archer SL; Stenmark KR; MacLean MR; Lang IM; Christman BW; Weir EK; Eickelberg O; Voelkel NF; Rabinovitch M
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):13S-24S. PubMed ID: 15194174
[TBL] [Abstract][Full Text] [Related]
2. Current insights on the pathogenesis of pulmonary arterial hypertension.
Perros F; Dorfmüller P; Humbert M
Semin Respir Crit Care Med; 2005 Aug; 26(4):355-64. PubMed ID: 16121311
[TBL] [Abstract][Full Text] [Related]
3. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension.
Humbert M; Montani D; Perros F; Dorfmüller P; Adnot S; Eddahibi S
Vascul Pharmacol; 2008; 49(4-6):113-8. PubMed ID: 18606248
[TBL] [Abstract][Full Text] [Related]
4. [Novel concepts in the pathobiology of pulmonary arterial hypertension].
Rosenkranz S
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S167-9. PubMed ID: 18814087
[TBL] [Abstract][Full Text] [Related]
5. [The etiopathogenesis of pulmonary hypertension: inflammation, vascular remodeling].
Kayikçioğlu M
Anadolu Kardiyol Derg; 2010 Aug; 10 Suppl 1():5-8. PubMed ID: 20819761
[TBL] [Abstract][Full Text] [Related]
6. Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure.
Ray L; Mathieu M; Jespers P; Hadad I; Mahmoudabady M; Pensis A; Motte S; Peters IR; Naeije R; McEntee K
Exp Physiol; 2008 Mar; 93(3):434-42. PubMed ID: 17993509
[TBL] [Abstract][Full Text] [Related]
7. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension.
Dumas de la Roque E; Savineau JP; Bonnet S
Pharmacol Ther; 2010 May; 126(2):186-99. PubMed ID: 20206649
[TBL] [Abstract][Full Text] [Related]
8. Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets.
Mercier O; Sage E; de Perrot M; Tu L; Marcos E; Decante B; Baudet B; Hervé P; Dartevelle P; Eddahibi S; Fadel E
J Thorac Cardiovasc Surg; 2009 Jun; 137(6):1538-46. PubMed ID: 19464477
[TBL] [Abstract][Full Text] [Related]
9. Pathobiology of pulmonary arterial hypertension.
Naeije R; Rondelet B
Bull Mem Acad R Med Belg; 2004; 159(Pt 2):219-26. PubMed ID: 15615096
[TBL] [Abstract][Full Text] [Related]
10. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension.
Peled N; Shitrit D; Fox BD; Shlomi D; Amital A; Bendayan D; Kramer MR
J Rheumatol; 2009 May; 36(5):970-5. PubMed ID: 19369472
[TBL] [Abstract][Full Text] [Related]
11. Endothelial progenitor cells in pulmonary arterial hypertension.
Diller GP; Thum T; Wilkins MR; Wharton J
Trends Cardiovasc Med; 2010 Jan; 20(1):22-9. PubMed ID: 20685574
[TBL] [Abstract][Full Text] [Related]
12. Current therapeutics and practical management strategies for pulmonary arterial hypertension.
Agarwal R; Gomberg-Maitland M
Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279
[TBL] [Abstract][Full Text] [Related]
13. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
[TBL] [Abstract][Full Text] [Related]
14. Pathologic assessment of vasculopathies in pulmonary hypertension.
Pietra GG; Capron F; Stewart S; Leone O; Humbert M; Robbins IM; Reid LM; Tuder RM
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):25S-32S. PubMed ID: 15194175
[TBL] [Abstract][Full Text] [Related]
15. [Physiopathology of pulmonary arterial hypertension. Cellular and molecular aspects].
Perros F; Humbert M
Presse Med; 2005 Feb; 34(3):232-42. PubMed ID: 15798538
[TBL] [Abstract][Full Text] [Related]
16. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
17. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension.
Mandegar M; Fung YC; Huang W; Remillard CV; Rubin LJ; Yuan JX
Microvasc Res; 2004 Sep; 68(2):75-103. PubMed ID: 15313118
[TBL] [Abstract][Full Text] [Related]
18. Mediators involved in HIV-related pulmonary arterial hypertension.
Humbert M
AIDS; 2008 Sep; 22 Suppl 3():S41-7. PubMed ID: 18845921
[TBL] [Abstract][Full Text] [Related]
19. Coagulation and anticoagulation in pulmonary arterial hypertension.
Berger G; Azzam ZS; Hoffman R; Yigla M
Isr Med Assoc J; 2009 Jun; 11(6):376-9. PubMed ID: 19697592
[TBL] [Abstract][Full Text] [Related]
20. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
Jacobs A; Preston IR; Gomberg-Maitland M
Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
